Image Credit: azimmytws / Shutterstock.com A recent BMJ study determines whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists by type 2 diabetes (T2D) patients increases the risk of self-harm, suicidal ideation, and suicide as compared to patients prescribed dipeptidyl peptidase-4 (DPP-4) or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Shima Hadidchi MD Family Practice is to support patients in achieving their weight-loss objectives safely and effectively, utilizing evidence-based treatments such as GLP-1 receptor agonists, alongside personalized lifestyle counseling and ongoing clinical support
Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations
doi: 10.2174/1570159X14666160219131357 182 SlyepchenkoA.MaesM.KohlerC
& Hall, M
Limitations: As with all GLP-1 therapies, ongoing monitoring for gastrointestinal side effects and potential hypoglycemia (especially in combination with a sulfonylurea) remains crucial